Patent EP 2 203 462 B1 relates to sofosbuvir for treatment of a hepatitis C infection in mammals.
Brief outline of the case
The OD decided that the patent as granted added subject-matter because the application as filed did not disclose the individual diastereomers depicted in claims 2 and 3, but AR1 consisting of claims 1 and 4 as granted was allowable.